After its efficacy was demonstrated in a clinical trial, the US Food and Drug Administration approved a new treatment options for adult patients with 2 types of poor-prognosis acute myeloid leukemia.
After results from a recent trial demonstrated its efficacy, the FDA expanded the indication of a cancer drug to include adult patients with chronic graft versus host disease who do not respond to other...
After results from a recent trial demonstrated its efficacy, the FDA expanded the indication of a cancer drug to include adult patients with chronic graft versus host disease who do not respond to other...
After results from a recent trial demonstrated its efficacy, the FDA expanded the indication of a cancer drug to include adult patients with chronic graft versus host disease who do not respond to other...
The FDA granted accelerated approval to a new treatment for adolescent and adult patients with mismatch repair deficient and microsatellite instability metastatic colorectal cancer.
The FDA granted accelerated approval to a new treatment for adolescent and adult patients with mismatch repair deficient and microsatellite instability metastatic colorectal cancer.
The FDA granted accelerated approval to a new treatment for adolescent and adult patients with mismatch repair deficient and microsatellite instability metastatic colorectal cancer.
The US Food and Drug Administration recently approved a new treatment option for patients with relapsed or refractory acute myeloid leukemia who have IDH2 mutations.
